Screening for adsorption, distribution, metabolism, excretion, and toxicology (ADMET) presents challenges that are at least an order of magnitude more complex than those found in screening for hits and even validation of hits at the secondary screening stage. Will the sets of Biomarkers identified in genomics, proteomics and/or metabolomics provide a foundation from which to develop more predictive assays for ADMET? This year`s discussion will be focused on a evaluation of ADMET assays from the perspective of their predictive value and strategies of their use in making decisions at different stages of drug discovery.